|
May 23, 2012
|
| 07:10 EDT |  | PFE, JNJ |
| theflyonthewall.com: | FTC, Senate probing blocking of generic drug companies, Washington Post says | | The Federal Trade Commission and the U.S. Senate are investigating whether pharmaceutical companies are using a loophole to prevent generic drug makers from obtaining samples of brand name drugs, according to The Washington Post. The FDA requires generic drug makers to test a sample of brand name versions in order to get a generic drug approved, the newspaper notes. Reference Link :theflyonthewall.com |
|
|
May 22, 2012
|
| 09:38 EDT |  | AUXL |
| theflyonthewall.com: | Auxilium upgraded to Buy from Neutral at MKM Partners (pre-open) | | :theflyonthewall.com |
|
| 08:27 EDT |  | VRTX |
| theflyonthewall.com: | BofA/Merrill's senior biotech analyst holds a conference call | | Senior Biotech Analyst McMinn provides an overview of cystic fibrosis and discusses Vertex Pharmaceuticals' market opportunity on an Analyst/Industry conference call to be held on May 22 at 4:15 pm. :theflyonthewall.com |
|
|
May 21, 2012
|
| 16:54 EDT |  | ITMN |
| theflyonthewall.com: | InterMune to divest Actimmune | | InterMune announced that it has reached a definitive agreement with Vidara Therapeutics International Limited to sell its rights to Actimmune in a cash transaction valued at $55M plus a two-year royalty stream. Vidara is part of an international specialty pharmaceutical group of companies with operations in Ireland and the United States. The transaction with Vidara is expected to close during 2Q12, subject to satisfaction of certain closing conditions. :theflyonthewall.com |
|
| 14:38 EDT | | JNJ |
| theflyonthewall.com: | Janssen presents data from Phase 3 study of anti-TNF Simponi | | Janssen Research & Development said that new study findings show that subcutaneous induction regimens of the anti-tumor necrosis factor-alpha therapy Simponi induced clinical response in a majority of patients with moderately to severely active ulcerative colitis who had previously failed or were intolerant to conventional agents. Investigators presented data from the Janssen-sponsored Phase 3 study at Digestive Disease Week during a late breaker session and reported that more than 50% of patients in each of two Simponi dosing groups achieved clinical response at week 6, the primary endpoint of the study, which was significantly more than those in clinical response after receiving placebo. Treatment with Simponi also resulted in significant induction of clinical remission and mucosal healing and improvement in health-related quality of life measures at week 6 compared with placebo, Janssen said. :theflyonthewall.com |
|
| 09:43 EDT | | JNJ |
| theflyonthewall.com: | Johnson & Johnson management to meet with JPMorgan | | Meeting to be held in Boston on May 24 hosted by JP Morgan. :theflyonthewall.com |
|
| 07:38 EDT | | PFE, NVS |
|
| 07:04 EDT |  | AUXL |
|
| 07:03 EDT | | AUXL |
| theflyonthewall.com: | Auxilium raises FY12 global Testim revenue to $225M-$235M from $215M-$225M | | :theflyonthewall.com |
|
| 07:03 EDT | | AUXL |
|
| 07:02 EDT | | AUXL |
| theflyonthewall.com: | Auxilium, GlaxoSmithKline enter co-promotion agreement for Testim | | Auxilium (AUXL) and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline (GSK), announced that they have entered into an agreement for the co-promotion of Testim 1%, which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone. :theflyonthewall.com |
|
| 06:40 EDT |  | ITMN |
|
|
May 18, 2012
|
| 14:04 EDT | | PFE |
| theflyonthewall.com: | Pfizer recalls Advil medicine, WSJ reports | | Pfizer (PFE) recently recalled more than 650,000 bottles of its Advil pain relief medicine because the pills could emit a strong odor, according to The Wall Street Journal. Reference Link :theflyonthewall.com |
|
| 13:34 EDT | | NVS |
|
| 10:27 EDT |  | ACOR, BMY |
| theflyonthewall.com: | On The Fly: Analyst Initiation Summary | | Today's noteworthy initiations include: Acorda Therapeutics (ACOR) initiated with a Sell at Goldman... Bristol-Myers (BMY) initiated with an Outperform at BMO Capital... Corning (GLW) initiated with a Neutral at Susquehanna... Cree (CREE) initiated with a Positive at Susquehanna... Exactech (EXAC) initiated with a Buy at Benchmark Co... Hawaiian Holdings (HA) initiated with an Outperform at Imperial Capital... Mattel (MAT) initiated with a Buy at SunTrust... Merck (MRK) initiated with a Market Perform at BMO Capital... Micron (MU) initiated with a Buy at ThinkEquity... SanDisk (SNDK) initiated with a Hold at ThinkEquity... Spansion (CODE) initiated with a Buy at ThinkEquity... Dendreon (DNDN) initiated with a Sell at Maxim. :theflyonthewall.com |
|
| 08:04 EDT | | PFE |
|
| 07:59 EDT | | BMY |
|
| 06:32 EDT | | BMY |
|
| 05:52 EDT | | ACOR |
|
| 05:35 EDT | | BMY |
| theflyonthewall.com: | Dr. Reddy's Labs announces the launch of Clopidogrel tablets, USP | | Dr. Reddy’s Laboratories announced that it has launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a bioequivalent generic version of PLAVIX, in the U.S. market on May 18. The ANDAs for Clopidogrel Tablets USP, 75 mg & 300 mg are approved by the U.S. FDA, or USFDA. Dr. Reddy’s Laboratories was among the first applicants to submit a substantially complete ANDA for Clopidogrel Tablets USP, 300 mg with a Paragraph IV certification, and was awarded 180 days of marketing exclusivity for this strength. The PLAVIX brand had U..S. sales of approximately $6.740B for the most recent twelve months ending March 2012 according to IMS Health. :theflyonthewall.com |
|
|
May 17, 2012
|
| 17:45 EDT | | PFE |
|
| 15:47 EDT | | BMY |
|
| 14:17 EDT | | ITMN |
| theflyonthewall.com: | InterMune management to meet with JMP Securities | | Meeting to be held in Brisbane, CA on May 22 hosted by JMP Securities. :theflyonthewall.com |
|
| 13:15 EDT | | HGSI |
| theflyonthewall.com: | GlaxoSmithKline to proceed with tender offer for Human Genome | | GlaxoSmithKline (GSK) commented on Human Genome Sciences' (HGSI) decision to recommend against GSK's tender offer to acquire all of the outstanding shares of HGS for $13.00 per share in cash. GSK said it believes the offer represents full and fair value and is in the best interests of both companies' shareholders. GSK added that it will continue to proceed with its tender offer and "clearly stated its preference to complete a transaction on a friendly basis in a timely fashion." The tender offer will close on June 7. :theflyonthewall.com |
|
| 10:55 EDT | | VRTX |
|
| 08:18 EDT | | GILD |
| theflyonthewall.com: | Gilead likey to remain dominant in HIV treatment for some time, says Wells Fargo |
 Subscribe for More Information :theflyonthewall.com |
|
| 07:12 EDT | | HGSI |
| theflyonthewall.com: | Human Genome says in talks with a number of other parties | | Human Genome said that with the assistance of advisors, it continues to to explore strategic alternatives to maximize value, including, but not limited to, a sale of the company. As part of this process, the company’s management has engaged in discussions with a number of other parties, including major pharmaceutical and biotechnology companies, regarding a potential transaction, has entered into confidentiality agreements with certain parties and is providing those parties an opportunity to engage in a due diligence review of confidential information. Human Genome added, "While the Board has not made any decision to sell the Company, the Board believes that the Offer must be evaluated against the Company’s well established long-term strategy for stockholder value creation and the prospect of other potential transactions which, if consummated, could yield greater long- or short-term value to stockholders than the Offer." :theflyonthewall.com |
|
| 07:02 EDT | | HGSI |
|
| 07:01 EDT | | HGSI |
|
| 07:01 EDT | | HGSI |
|
| 07:01 EDT | | AUXL |
|
| 06:32 EDT |  | HGSI |
| theflyonthewall.com: | Stocks with implied volatility movement; MCP HGSI | | Stocks with implied volatility movement: Molycorp (MCP), Human Genome (HGSI) according to iVolatility. :theflyonthewall.com |
|
| 06:02 EDT | | PFE |
|
| 05:01 EDT | | NVS |
|
|
May 16, 2012
|
| 18:58 EDT | | ACOR |
|
| 18:11 EDT | | AMGN |
| theflyonthewall.com: | Amgen's Rilotumumab data identifies potential predictive biomarker | | Amgen announced results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab, or AMG 102. This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with rilotumumab in combination with chemotherapy improved median overall survival in patients whose tumors exhibited high MET protein expression. :theflyonthewall.com |
|
| 18:09 EDT | | AMGN |
|
| 12:54 EDT | | BMY |
|
| 11:10 EDT | | ACOR |
|
|
May 15, 2012
|
| 17:10 EDT | | PFE |
| theflyonthewall.com: | Pfizer reports positive results for Phase 3 Intorsect study evaluating Torisel | | Pfizer announced that the Phase 3 INTORSECT study, evaluating TORISEL in patients with advanced renal cell carcinoma whose disease had progressed on or after SUTENT therapy, did not meet the primary endpoint of prolonging progression free survival when compared to sorafenib. Although PFS was numerically higher in patients treated with temsirolimus, the difference was not statistically significant. Overall survival, a secondary endpoint in the study, showed statistical significance favoring patients randomized to the sorafenib arm. Adverse events in this study were consistent with the known safety profiles for both drugs. Full efficacy and safety data from this study will be presented at an upcoming major medical congress. :theflyonthewall.com |
|
| 11:01 EDT | | BMY |
|
| 10:36 EDT | | AMLN |
|
| 10:09 EDT | | BMY, AMLN, PFE |
|
| 09:38 EDT | | BMY, AMLN |
| theflyonthewall.com: | Amylin takeover could get done in mid-$30's per share, says Leerink | | Leerink is not surprised by the number of potential bidders reportedly interested in Amylin (AMLN) and says a deal for the company could get done reasonably in the mid-$30 per share range for the right acquirer. The firm thinks a bidding war could push the takeover price even higher. Leerink views Amylin as being the most strategic for Sanofi (SNY), followed by Merck (MRK), and believes and Bristol-Myers' (BMY) purported $22 per share bid sets a floor for any acquisition offer. :theflyonthewall.com |
|
| 09:37 EDT | | PFE, JNJ |
|
| 09:01 EDT |  | AMLN |
| theflyonthewall.com: | Amylin moves up on potential bid interest report, resistance at $27.50 | | :theflyonthewall.com |
|
| 07:24 EDT | | AMLN, PFE |
|
| 06:55 EDT | | VRTX |
|
| 06:10 EDT | | AMLN, PFE |
|
| 05:40 EDT | | BMY |
| theflyonthewall.com: | Bristol-Myers Squibb and Tsinghua University enter strategic partnership | | Bristol-Myers Squibb and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University’s School of Life Sciences to identify and validate novel targets in oncology and immunoscience. The collaboration will also focus on structural biology research, the science of mapping the 3D protein structure of biological molecular targets that could serve as the basis for future drug discovery projects. :theflyonthewall.com |
|
|
May 14, 2012
|
| 10:24 EDT | | VRTX |
| theflyonthewall.com: | On The Fly: Analyst Upgrade Summary | | Today's noteworthy upgrades include: Arch Coal (ACI) upgraded to Buy from Neutral at UBS... Ares Capital (ARCC) upgraded to Equal Weight from Underweight at Barclays... Career Education (CECO) upgraded to Market Perform from Underperform at BMO Capital... Citi Trends (CTRN) upgraded to Outperform from Market Perform at Wells Fargo... Louisiana Pacific (LPX) upgraded to Outperform from Sector Perform at RBC Capital... McDermott (MDR) upgraded to Overweight from Neutral at JPMorgan... NetSuite (N) upgraded to Conviction Buy from Buy at Goldman... PDC Energy (PETD) upgraded to Buy from Hold at Canaccord... St. Jude Medical (STJ) upgraded to Buy from Neutral at Goldman... Teradata (TDC) upgraded to Overweight from Equal Weight at Barclays... Ultimate Software (ULTI) upgraded to Buy from Sell at Goldman... Vertex Pharmaceuticals (VRTX) upgraded to Overweight from Neutral at JPMorgan... Pulte Group (PHM) upgraded to Buy from Neutral at Guggenheim... Ryland Group (RYL) upgraded to Buy from Sell at Guggenheim... Toll Brothers (TOL) upgraded to Buy from Neutral at Guggenheim... NVIDIA (NVDA) upgraded to Average from Below Average at Cari. :theflyonthewall.com |
|
| 09:15 EDT | | VRTX |
|
| 08:05 EDT | | PFE |
|
| 08:03 EDT | | BMY |
|
| 08:03 EDT | | BIIB |
|
| 08:00 EDT | | AUXL |
|
| 07:45 EDT | | GILD |
| theflyonthewall.com: | Gilead Quad approval will be important, says RW Baird | | Baird said Gilead received an expected FDA panel vote in favor of approving Quad. The firm believes Quad could be the most important product for the company to improve its margins and allow it to sustain its dominant franchise in the coming years. Shares are Outperform rated with a $59 price target. :theflyonthewall.com |
|
| 06:48 EDT | | VRTX |
|
| 06:42 EDT | | JNJ |
|
|
May 11, 2012
|
| 15:34 EDT | | GILD |
|
| 14:38 EDT | | GILD |
|
| 13:11 EDT | | AUXL |
|
| 08:02 EDT | | JNJ |
| theflyonthewall.com: | Study reports catheter ablation superior to drug therapy as AF treatment | | Patients with the heart rhythm disorder atrial fibrillation who received first-line catheter ablation treatment had a longer arrhythmia-free interval than patients receiving antiarrhythmic drugs, the standard first-line treatment. The preliminary findings were presented during a late-breaking session at Heart Rhythm 2012, the Society’s 33rd Annual Scientific Sessions in Boston. The study found that, compared to treatment with antiarrhythmic drugs, radiofrequency catheter ablation significantly extended the time to first recurrence of AFib, atrial tachyarrhythmia, atrial flutter and asymptomatic AFib, in patients with paroxysmal recurrent AFib who had not been previously treated with an antiarrhythmic drug. The study was sponsored by the Population Health Research Institute, McMaster University and Hamilton Health Sciences and funded by a research grant from Biosense Webster, a Johnson & Johnson company. :theflyonthewall.com |
|
| 07:50 EDT | | AUXL |
|
| 07:36 EDT | | GILD |
|
| 07:32 EDT | | PFE |
| theflyonthewall.com: | Mylan launches generic version of Pfizer's Lipitor in five European countries | | Mylan (MYL) announced that it has launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg in France, Belgium, the U.K., the Netherlands and Ireland. Mylan has received marketing authorization from each country's respective health authority to begin selling its product immediately. Atorvastatin Calcium is the generic version of Pfizer's (PFE) Lipitor Tablets. :theflyonthewall.com |
|
| 07:06 EDT | | JNJ |
|
| 05:40 EDT | | GILD |
| theflyonthewall.com: | Gilead: FDA advisory committee supports approval of Truvada to prevent HIV | | Gilead Sciences announced that the Antiviral Drugs Advisory Committee of the U.S. FDA has voted to support approval of once-daily oral Truvada to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP. If the FDA decides to approve Truvada for PrEP, it would be the first agent indicated for uninfected individuals to reduce their risk of acquiring HIV. The recommendations of the Advisory Committee are not binding, but will be considered by the FDA as the agency completes its six-month priority review of Gilead’s supplemental New Drug Application, or sNDA, of Truvada for PrEP. Gilead submitted the sNDA on Dec. 15, and the FDA has established a target review date under the Prescription Drug User Fee Act, or PDUFA. of June 15. :theflyonthewall.com |
|
|
May 10, 2012
|
| 17:27 EDT |  | PFE |
| theflyonthewall.com: | Pfizer files automatic mixed securities shelf | | :theflyonthewall.com |
|
| 12:06 EDT | | HGSI |
|
| 10:28 EDT |  | VRTX, HGSI |
| theflyonthewall.com: | On The Fly: Analyst Downgrade Summary | | Today's noteworthy downgrades include: AMAG Pharmaceuticals (AMAG) downgraded to Neutral from Outperform at RW Baird... AboveNet (ABVT) downgraded to Market Perform from Outperform at Wells Fargo... Aon Corp. (AON) downgraded to Neutral from Outperform at Macquarie... Arthur J. Gallagher (AJG) downgraded to Neutral from Outperform at Macquarie... Dolby (DLB) downgraded to Neutral from Overweight at JPMorgan... DTS, Inc. (DTSI) downgraded to Underweight from Neutral at JPMorgan... ECA Marcellus (ECT) downgraded to Sector Perform from Outperform at RBC Capital... Extra Space Storage (EXR) downgraded to Hold from Buy at Jefferies... Highwoods Properties (HIW) downgraded to Hold from Buy at Jefferies... Human Genome (HGSI) downgraded to Market Perform from Outperform at Leerink... Martin Marietta (MLM) downgraded to Sector Perform from Outperform at RBC Capital... PartnerRe (PRE) downgraded to Neutral from Buy at Citigroup... Unum Group (UNM) downgraded to Equal Weight from Overweight at Evercore... Vail Resorts (MTN) downgraded to Market Perform from Outperform at Wells Fargo... Vertex Pharmaceuticals (VRTX) downgraded to Outperform from Top Pick at RBC Capital... Staples (SPLS) downgraded to Sell from Hold at ISI Group. :theflyonthewall.com |
|
| 10:07 EDT | | BIIB |
|
| 08:36 EDT | | HGSI |
|
| 08:15 EDT | | NVS |
| theflyonthewall.com: | Novartis to investigate alleged approval irregularities in India, Reuters says | | Novartis (NVS) says it will investigate alleged drug approval irregularities in India after a parliamentary report found the country's regulator colluded with pharmaceutical companies to speed up approval procedures, reports Reuters. Reference Link :theflyonthewall.com |
|
| 07:38 EDT | | GILD |
|
| 07:16 EDT | | JNJ |
| theflyonthewall.com: | Johnson & Johnson's Biosense Webster launches Thermocool ablation catheter | | Johnson & Johnson's Biosense Webster launched the new THERMOCOOL SF NAV irrigated ablation catheter with Curve Visualization in the United States. The catheter with curve visualization combines Biosense Webster’s latest porous tip technology with the visualization of the CARTO3 3D Mapping & Ablation System, designed to reduce fluoroscopy exposure to physicians, lab staff and patients alike, enhance visualization of the ablation catheters orientation and improve procedural efficiency. :theflyonthewall.com |
|
| 07:11 EDT | | PFE |
|
| 07:01 EDT | | AUXL |
|
| 06:58 EDT | | AMLN |
|
| 06:30 EDT | | VRTX |
| theflyonthewall.com: | Vertex Pharmaceuticals downgraded to Outperform from Top Pick at RBC Capital | | RBC Capital remains bullish on Vertex but sees higher risk at current levels. Price target raised to $69 from $63. :theflyonthewall.com |
|
| 06:21 EDT | | HGSI |
| theflyonthewall.com: | Human Genome downgraded to Market Perform from Outperform at Leerink | | Leerink downgraded Human Genome (HGSI) citing limited upside visibility after GlaxoSmithKline (GSK) decided to go hostile with its $13 per share offer for the company. The firm lowered its price target for shares to $16 from $22 as it believes Human Genome may be able to get GSK to up its offer by a couple of dollars, but not much more. :theflyonthewall.com |
|
| 06:18 EDT | | PFE |
|
| 06:05 EDT | | NVS |
| theflyonthewall.com: | Novartis initiated with a Buy at Societe Generale | | :theflyonthewall.com |
|
|
May 9, 2012
|
| 16:22 EDT | | BIIB |
| theflyonthewall.com: | US, EU regulators accept oral BG-12 marketing applications for review | | Biogen Idec announced that U.S. and EU regulatory authorities have accepted the company’s marketing applications for the review of BG-12, an oral therapeutic candidate for the treatment of multiple sclerosis. The U.S. Food and Drug Administration has accepted Biogen Idec’s New Drug Application for marketing approval of BG-12 in the United States and granted the company a standard review timeline. In addition, the European Medicines Agency has validated Biogen Idec’s Marketing Authorisation Application for review of BG-12 in the European Union. Biogen Idec announced that it submitted an NDA to the FDA and an MAA to the EMA in Q1. The company also recently submitted regulatory applications in Canada and Switzerland. :theflyonthewall.com |
|
| 15:36 EDT | | GILD |
|
| 15:20 EDT | | PFE |
| theflyonthewall.com: | Pfizer confirms FDA advisory committee's approval recommendation for Tofacitinib |
Subscribe for More Information :theflyonthewall.com |
|
| 14:53 EDT | | PFE |
| theflyonthewall.com: | Pfizer jumps, up 2.5% after FDA panel votes to back approval of arthritis drug |
Subscribe for More Information :theflyonthewall.com |
|
| 14:45 EDT | | PFE |
| theflyonthewall.com: | FDA panel backs approval of Pfizer's arthritis drug, Bloomberg reports | | :theflyonthewall.com |
|
| 14:35 EDT | | PFE |
|
| 14:30 EDT | | PFE |
| theflyonthewall.com: | FDA panel votes that Pfizer's tofacitinib is effective for arthritis treatment |
Subscribe for More Information :theflyonthewall.com |
|
| 14:25 EDT | | PFE |
|
| 10:08 EDT | | HGSI |
|
| 10:07 EDT | | HGSI |
|
| 08:44 EDT | | AMGN |
|
| 08:39 EDT | | AMGN |
| theflyonthewall.com: | Amgen says will continue to increase dividend "meaningfully" over time | | Says at end of Q1 had $3.6B in buyback authorization remaining, will continue to repurchase shares. :theflyonthewall.com |
|
| 08:36 EDT | | AMGN |
| theflyonthewall.com: | Amgen says continues to see stabilization in Aranesp business by mid-year | | Says ESA business now represents "much smaller" proportion of overall sales. Says declines in ESA business more than offset by revenue gains in denosumab franchise in Q1. :theflyonthewall.com |
|
| 08:33 EDT | | AMGN |
|
| 07:38 EDT | | GILD |
|
| 07:13 EDT | | PFE |
| theflyonthewall.com: | FDA Arthritis Advisory Committee to hold a meeting | | The Committee discusses Pfizer's New Drug Application (NDA) 203214, Tofacitinib tablets for treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs) in a meeting being held at FDA offices in Silver Spring, Maryland on May 9 at 8 am. Webcast Link :theflyonthewall.com |
|
| 07:04 EDT | | AUXL |
|
| 06:47 EDT | | AMLN |
|
| 06:00 EDT | | HGSI |
|
| 05:41 EDT | | HGSI |
| theflyonthewall.com: | GSK to launch tender offer to Human Genome shareholders, Reuters reports | | GlaxoSmithKline (GSK) will take its unsolicited $2.6B takeover bid for Human Genome Sciences (HGSI) directly to shareholders and launch a tender offer this week at $13 a share, reports Reuters. Reference Link :theflyonthewall.com |
|
| 04:53 EDT | | VRTX |
|
